Table 2.
Chemotherapy Regimens in Treatment and Control Groups
| Chemotherapy Regimen | No. (%) of Patients | |
|---|---|---|
| Scalp Cooling Group (n = 101)a | Control Group (n = 16) | |
| Docetaxel (75 mg/m2) and cyclophosphamide (600 mg/m2) for 4–6 cycles every 3 wk | 76 (75.2) | 10 (62.5) |
| Paclitaxel (80 mg/m2) weekly for 12 cycles | 12 (11.9) | 2 (12.5) |
| Docetaxel (75 mg/m2), carboplatin (area under the concentration time curve: 6) for 6 cycles every 3 wk, and trastuzumab weekly or every 3 wk with or without pertuzumab every 3 wk | 12 (11.9) | 3 (18.8) |
| Docetaxel (75 mg/m2), trastuzumab, and pertuzumab every 3 wk for 6 cycles | 1 (1.0) | 0 |
| Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) every 3 wk for 4 cycles | 0 | 1 (6.3) |
a
There were 5 patients who were not included in the primary analysis.